Abstract
8002 Background: The efficacy of the oral ALK inhibitor crizotinib as 1st-line treatment for advanced ALK-positive NSCLC compared with standard chemotherapy is unknown. A multicenter, randomized op...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have